Martin Christian

Martin Christian

Auto-generated profile, based on publicly available information

Martin Christian

Department of Paediatric Nephrology, Nottingham Children’s Hospital, Nottingham, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2021 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
MCMartin T. Christian
Martin T. Christian
NWNicholas J. A. Webb
Nicholas J. A. Webb
SMSamir Mehta
Samir Mehta
RWRebecca L. Woolley
Rebecca L. Woolley
NANafsika Afentou
Nafsika Afentou
NINatalie Ives
Natalie Ives
Steroid-sensitive nephrotic syndrome (SSNS) is the most common glomerular disease of childhood, with an incidence of approximately 2 per 100 000 children, although it is up to 6 times more common in children of South Asian ethnic origin.1 At least 80% of children with SSNS will relapse,2 and relapses are associated with a risk of significant complications, including sepsis, thrombosis, dyslipidemia, and malnutrition.3 At least 50% of relapses follow intercurrent infections, most commonly upper respiratory tract infections (URTIs)4-6; furthermore, in children with relapsing SSNS, half or more URTIs will trigger a relapse.7

27 April 2014 in Trials
Verified
Journal Article
Open access
PDF file
NWNicholas J A Webb
Nicholas J A Webb
EFEmma Frew
Emma Frew
EBElizabeth A Brettell
Elizabeth A Brettell
DMDavid Milford
David Milford
DBDetlef Bockenhauer
Detlef Bockenhauer
NINatalie J Ives
Natalie J Ives
Relapses of childhood steroid-sensitive nephrotic syndrome (SSNS) are treated with a 4- to 8-week course of high-dose oral prednisolone, which may be associated with significant adverse effects. There is a clear association between upper respiratory tract infection (URTI) and relapse development. Previous studies in developing nations have suggested that introducing a 5- to 7-day course of daily prednisolone during an URTI may prevent a relapse developing and the need for a treatment course of high-dose prednisolone. The aim of PREDNOS 2 is to evaluate the effectiveness of a 6-day course of daily prednisolone therapy during an URTI in reducing the development of a subsequent relapse in a developed nation.

20 February 2021 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
MCMartin T. Christian
Martin T. Christian
AMAndrew P. Maxted
Andrew P. Maxted

16 September 2021 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
JDJan Dudley
Jan Dudley
MCMartin Christian
Martin Christian
AAAlice Andrews
Alice Andrews
NANicola Andrews
Nicola Andrews
JBJulie Baker
Julie Baker
SMStephen Marks
Stephen Marks

1 January 2022 in Health Technology Assessment
Verified
Journal Article
Closed access
PDF file
MCMartin T Christian
Martin T Christian
NWNicholas Ja Webb
Nicholas Ja Webb
RWRebecca L Woolley
Rebecca L Woolley
NANafsika Afentou
Nafsika Afentou
SMSamir Mehta
Samir Mehta
NINatalie Ives
Natalie Ives
Background: Most children with steroid-sensitive nephrotic syndrome have relapses that are triggered by upper respiratory tract infections. Four small trials, mostly in children already taking maintenance corticosteroid in countries of different upper respiratory tract infection epidemiology, showed that giving daily low-dose prednisone/prednisolone for 5–7 days during an upper respiratory tract infection reduces the risk of relapse. Objectives: To determine if these findings were replicated in a large UK population of children with relapsing steroid-sensitive nephrotic syndrome on different background medication or none. Design: A randomised double-blind placebo-controlled trial, including a cost-effectiveness analysis. Setting: A total of 122 UK paediatric departments, of which 91 recruited patients. Participants: A total of 365 children with relapsing steroid-sensitive nephrotic syndrome (mean age 7.6 ± 3.5 years) were randomised (1 : 1) according to a minimisation algorithm based on background treatment. Eighty children completed 12 months of follow-up without an upper respiratory tract infection. Thirty-two children were withdrawn from the trial (14 prior to an upper respiratory tract infection), leaving a modified intention-to-treat analysis population of 271 children (134 and 137 children in the prednisolone and placebo arms, respectively). Interventions: At the start of an upper respiratory tract infection, children received 6 days of prednisolone (15 mg/m2) or an equivalent dose of placebo. Main outcome measures: The primary outcome was the incidence of first upper respiratory tract infection-related relapse following any upper respiratory tract infection over 12 months. The secondary outcomes were the overall rate of relapse, changes in background treatment, cumulative dose of prednisolone, rates of serious adverse events, incidence of corticosteroid adverse effects, change in Achenbach Child Behaviour Checklist score and quality of life. Analysis was by intention-to-treat principle. The cost-effectiveness analysis used trial data and a decision-analytic model to estimate quality-adjusted life-years and costs at 1 year, which were then extrapolated over 16 years. Results: There were 384 upper respiratory tract infections and 82 upper respiratory tract infection-related relapses in the prednisolone arm, and 407 upper respiratory tract infections and 82 upper respiratory tract infection-related relapses in the placebo arm. The number of patients experiencing an upper respiratory tract infection-related relapse was 56 (42.7%) and 58 (44.3%) in the prednisolone and placebo arms, respectively (adjusted risk difference –0.024, 95% confidence interval –0.14 to 0.09; p = 0.70). There was no evidence that the treatment effect differed when data were analysed according to background treatment. There were no significant differences in secondary outcomes between treatment arms. Giving daily prednisolone at the time of an upper respiratory tract infection was associated with increased quality-adjusted life-years (0.9427 vs. 0.9424) and decreased average costs (£252 vs. £254), when compared with standard care. The cost saving was driven by background therapy and hospitalisations after relapse. The finding was robust to sensitivity analysis. Limitations: A larger number of children than expected did not have an upper respiratory tract infection and the sample size attrition rate was adjusted accordingly during the trial. Conclusions: The clinical analysis indicated that giving 6 days of daily low-dose prednisolone at the time of an upper respiratory tract infection does not reduce the risk of relapse of steroid-sensitive nephrotic syndrome in UK children. However, there was an economic benefit from costs associated with background therapy and relapse, and the health-related quality-of-life impact of having a relapse. Future work: Further work is needed to investigate the clinical and health economic impact of relapses, interethnic differences in treatment response, the effect of different corticosteroid regimens in treating relapses, and the pathogenesis of individual viral infections and their effect on steroid-sensitive nephrotic syndrome. Trial registration: Current Controlled Trials ISRCTN10900733 and EudraCT 2012-003476-39. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 3. See the NIHR Journals Library website for further project information.